Purpose: This study examines the factors influencing 30-day in-hospital mortality in elderly patients with community-acquired pneumonia (CAP) and compares them to those in adult patients. Methods: This secondary analysis used discharge data from the Korea Disease Control and Prevention Agency, covering the period from January 1, 2020, to December 31, 2022. Statistical methods included χ² tests, t-tests, the Cox proportional hazards model for calculating adjusted hazard ratios (HR), and Kaplan-Meier analysis. Results: The study found that older age (Adjusted HR=2.40, 95% CI=2.01-2.85, p<.001) and Emergency Room admissions (Adjusted HR=2.24, 95% CI=1.94-2.59, p<.001) are significantly associated with increased mortality in elderly patients. Other contributing factors include residency area (Adjusted HR=1.73, 95% CI=1.04-2.87, p=.035), hospital setting (Adjusted HR=1.34, 95% CI=1.05-1.70, p=.017), and the number of hospital beds (Adjusted HR=1.27, 95% CI=1.11-1.46, p=.001). Conclusion These findings underscore the importance of improving community health screenings and developing respiratory infection prevention programs for elderly patients, especially those in high-risk areas.

Purpose: This study examines the factors influencing 30-day in-hospital mortality in elderly patients with community-acquired pneumonia (CAP) and compares them to those in adult patients. Methods: This secondary analysis used discharge data from the Korea Disease Control and Prevention Agency, covering the period from January 1, 2020, to December 31, 2022. Statistical methods included χ² tests, t-tests, the Cox proportional hazards model for calculating adjusted hazard ratios (HR), and Kaplan-Meier analysis. Results: The study found that older age (Adjusted HR=2.40, 95% CI=2.01-2.85, p<.001) and Emergency Room admissions (Adjusted HR=2.24, 95% CI=1.94-2.59, p<.001) are significantly associated with increased mortality in elderly patients. Other contributing factors include residency area (Adjusted HR=1.73, 95% CI=1.04-2.87, p=.035), hospital setting (Adjusted HR=1.34, 95% CI=1.05-1.70, p=.017), and the number of hospital beds (Adjusted HR=1.27, 95% CI=1.11-1.46, p=.001). Conclusion These findings underscore the importance of improving community health screenings and developing respiratory infection prevention programs for elderly patients, especially those in high-risk areas.

Purpose: This study examines the factors influencing 30-day in-hospital mortality in elderly patients with community-acquired pneumonia (CAP) and compares them to those in adult patients. Methods: This secondary analysis used discharge data from the Korea Disease Control and Prevention Agency, covering the period from January 1, 2020, to December 31, 2022. Statistical methods included χ² tests, t-tests, the Cox proportional hazards model for calculating adjusted hazard ratios (HR), and Kaplan-Meier analysis. Results: The study found that older age (Adjusted HR=2.40, 95% CI=2.01-2.85, p<.001) and Emergency Room admissions (Adjusted HR=2.24, 95% CI=1.94-2.59, p<.001) are significantly associated with increased mortality in elderly patients. Other contributing factors include residency area (Adjusted HR=1.73, 95% CI=1.04-2.87, p=.035), hospital setting (Adjusted HR=1.34, 95% CI=1.05-1.70, p=.017), and the number of hospital beds (Adjusted HR=1.27, 95% CI=1.11-1.46, p=.001). Conclusion These findings underscore the importance of improving community health screenings and developing respiratory infection prevention programs for elderly patients, especially those in high-risk areas.

Purpose: This study aimed to compare symptoms, social support, and quality of life across different stages of survival in patients with lung cancer. Methods: The study included 145 participants: 49 in the acute survival phase (less than 2 years), 50 in the extended survival phase (2~5 years), and 46 in the lasting survival phase (> 5 years). A structured questionnaire was utilized to assess symptoms, social support, and quality of life. Analysis of covariance was used to control for demographic and disease-related variables. Results: Quality of life was significantly higher in the lasting survival stage (F=5.05, p=.008). The severity of symptoms was highest in the acute survival stage, followed by the extended survival stage, and lowest in the lasting survival stage (F=15.79, p<.001). Symptom interference with life was greater in the extended survival stage than in the lasting survival stage (F=11.11, p<.001). Social support was the lowest in the extended survival stage (F=10.03, p<.001). Notably, the extended survival stage had the highest scores for symptoms affecting daily activities, relationships, walking, and work (p<.001). Conclusion This study highlights the differences in symptoms, social support, and quality of life in patients with lung cancer across their survival stages. Tailored interventions are essential for each survival stage to improve the quality of life, with emotional and social support being critical in the extended survival phase, whereas symptom management is key in the acute phase.

Purpose: This study aimed to compare symptoms, social support, and quality of life across different stages of survival in patients with lung cancer. Methods: The study included 145 participants: 49 in the acute survival phase (less than 2 years), 50 in the extended survival phase (2~5 years), and 46 in the lasting survival phase (> 5 years). A structured questionnaire was utilized to assess symptoms, social support, and quality of life. Analysis of covariance was used to control for demographic and disease-related variables. Results: Quality of life was significantly higher in the lasting survival stage (F=5.05, p=.008). The severity of symptoms was highest in the acute survival stage, followed by the extended survival stage, and lowest in the lasting survival stage (F=15.79, p<.001). Symptom interference with life was greater in the extended survival stage than in the lasting survival stage (F=11.11, p<.001). Social support was the lowest in the extended survival stage (F=10.03, p<.001). Notably, the extended survival stage had the highest scores for symptoms affecting daily activities, relationships, walking, and work (p<.001). Conclusion This study highlights the differences in symptoms, social support, and quality of life in patients with lung cancer across their survival stages. Tailored interventions are essential for each survival stage to improve the quality of life, with emotional and social support being critical in the extended survival phase, whereas symptom management is key in the acute phase.

Purpose: This study examines the factors influencing 30-day in-hospital mortality in elderly patients with community-acquired pneumonia (CAP) and compares them to those in adult patients. Methods: This secondary analysis used discharge data from the Korea Disease Control and Prevention Agency, covering the period from January 1, 2020, to December 31, 2022. Statistical methods included χ² tests, t-tests, the Cox proportional hazards model for calculating adjusted hazard ratios (HR), and Kaplan-Meier analysis. Results: The study found that older age (Adjusted HR=2.40, 95% CI=2.01-2.85, p<.001) and Emergency Room admissions (Adjusted HR=2.24, 95% CI=1.94-2.59, p<.001) are significantly associated with increased mortality in elderly patients. Other contributing factors include residency area (Adjusted HR=1.73, 95% CI=1.04-2.87, p=.035), hospital setting (Adjusted HR=1.34, 95% CI=1.05-1.70, p=.017), and the number of hospital beds (Adjusted HR=1.27, 95% CI=1.11-1.46, p=.001). Conclusion These findings underscore the importance of improving community health screenings and developing respiratory infection prevention programs for elderly patients, especially those in high-risk areas.

Purpose: This study aimed to compare symptoms, social support, and quality of life across different stages of survival in patients with lung cancer. Methods: The study included 145 participants: 49 in the acute survival phase (less than 2 years), 50 in the extended survival phase (2~5 years), and 46 in the lasting survival phase (> 5 years). A structured questionnaire was utilized to assess symptoms, social support, and quality of life. Analysis of covariance was used to control for demographic and disease-related variables. Results: Quality of life was significantly higher in the lasting survival stage (F=5.05, p=.008). The severity of symptoms was highest in the acute survival stage, followed by the extended survival stage, and lowest in the lasting survival stage (F=15.79, p<.001). Symptom interference with life was greater in the extended survival stage than in the lasting survival stage (F=11.11, p<.001). Social support was the lowest in the extended survival stage (F=10.03, p<.001). Notably, the extended survival stage had the highest scores for symptoms affecting daily activities, relationships, walking, and work (p<.001). Conclusion This study highlights the differences in symptoms, social support, and quality of life in patients with lung cancer across their survival stages. Tailored interventions are essential for each survival stage to improve the quality of life, with emotional and social support being critical in the extended survival phase, whereas symptom management is key in the acute phase.

Purpose: This study examines the factors influencing 30-day in-hospital mortality in elderly patients with community-acquired pneumonia (CAP) and compares them to those in adult patients. Methods: This secondary analysis used discharge data from the Korea Disease Control and Prevention Agency, covering the period from January 1, 2020, to December 31, 2022. Statistical methods included χ² tests, t-tests, the Cox proportional hazards model for calculating adjusted hazard ratios (HR), and Kaplan-Meier analysis. Results: The study found that older age (Adjusted HR=2.40, 95% CI=2.01-2.85, p<.001) and Emergency Room admissions (Adjusted HR=2.24, 95% CI=1.94-2.59, p<.001) are significantly associated with increased mortality in elderly patients. Other contributing factors include residency area (Adjusted HR=1.73, 95% CI=1.04-2.87, p=.035), hospital setting (Adjusted HR=1.34, 95% CI=1.05-1.70, p=.017), and the number of hospital beds (Adjusted HR=1.27, 95% CI=1.11-1.46, p=.001). Conclusion These findings underscore the importance of improving community health screenings and developing respiratory infection prevention programs for elderly patients, especially those in high-risk areas.

Aromadendrin is a phenolic compound with various biological effects such as anti-inflammatory properties. However, its protective effects against acute lung injury (ALI) remain unclear. Therefore, this study aimed to explore the ameliorative effects of aromadendrin in an experimental model of lipopolysaccharide (LPS)-induced ALI. In vitro analysis revealed a notable increase in the levels of cytokine/chemokine formation, nuclear factor kappa B (NF-κB) activation, and myeloid differentiation primary response 88 (MyD88)/toll-like receptor (TLR4) expression in LPS-stimulated BEAS-2B lung epithelial cell lines that was ameliorated by aromadendrin pretreatment. In LPS-induced ALI mice, the remarkable upregulation of immune cells and IL-1β/IL-6/TNF-α levels in the bronchoalveolar lavage fluid and inducible nitric oxide synthase/cyclooxygenase-2/CD68 expression in lung was decreased by the oral administration of aromadendrin. Histological analysis revealed the presence of cells in the lungs of ALI mice, which was alleviated by aromadendrin. In addition, aromadendrin ameliorated lung edema. This in vivo effect of aromadendrin was accompanied by its inhibitory effect on LPS-induced NF-κB activation, MyD88/TLR4 expression, and signal transducer and activator of transcription 3 activation. Furthermore, aromadendrin increased the expression of heme oxygenase-1/ NAD(P)H quinone dehydrogenase 1 in the lungs of ALI mice. In summary, the in vitro and in vivo studies demonstrated that aromadendrin ameliorated endotoxin-induced pulmonary inflammation by suppressing cytokine formation and NF-κB activation, suggesting that aromadendrin could be a useful adjuvant in the treatment of ALI.

Purpose: Recently, we developed allele-discriminating priming system (ADPS) technology. This method increases the sensitivity of conventional quantitative polymerase chain reaction up to 100 folds, with limit of detection, 0.01%, with reinforced specificity. This prospective study aimed to develop and validate the accuracy of ADPS epidermal growth factor receptor (EGFR) Mutation Test Kit using clinical specimens. Materials and Methods: In total 189 formalin-fixed paraffin-embedded tumor tissues resected from patients with non–small cell lung cancer were used to perform a comparative evaluation of the ADPS EGFR Mutation Test Kit versus the cobas EGFR Mutation Test v2, which is the current gold standard. When the two methods had inconsistent results, next-generation sequencing–based CancerSCAN was utilized as a referee. Results: The overall agreement of the two methods was 97.4% (93.9%-99.1%); the positive percent agreement, 95.0% (88.7%-98.4%); and the negative percent agreement, 100.0% (95.9%-100.0%). EGFR mutations were detected at a frequency of 50.3% using the ADPS EGFR Mutation Test Kit and 52.9% using the cobas EGFR Mutation Test v2. There were 10 discrepant mutation calls between the two methods. CancerSCAN reproduced eight ADPS results. In two cases, mutant allele fraction was ultra-low at 0.02% and 0.06%, which are significantly below the limit of detection of the cobas assay and CancerSCAN. Based on the EGFR genotyping by ADPS, the treatment options could be switched in five patients. Conclusion The highly sensitive and specific ADPS EGFR Mutation Test Kit would be useful in detecting the patients who have lung cancer with EGFR mutation, and can benefit from the EGFR targeted therapy.